Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | GABRP | O00591 | 6/20 | 0.45 |
| ▸ | GABRD | O14764 | 6/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 6/20 | 0.45 |
| ▸ | GABRE | P78334 | 6/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9273 | 0.90 | GABRP (0.53) | TNKSCA1CA2GABRPGABRD | |
| SCHEMBL8648 | 0.89 | TNKS (0.50) | TNKSCA1CA2GABRPGABRD | |
| SCHEMBL8910 | 0.86 | TNKS (0.52) | TNKSCA1CA2GABRPGABRD | |
| SCHEMBL8257 | 0.86 | GABRP (0.52) | CA1CA2GABRPGABRDGABRA1 | |
| SCHEMBL8665 | 0.84 | CA1 (0.59) | TNKSCA1CA2GABRPGABRD | |
| SCHEMBL16619367 | 0.84 | TNKS (0.50) | TNKSCA1CA2GABRPGABRD | |
| SCHEMBL15528315 | 0.84 | TNKS (0.50) | TNKSCA1CA2GABRPGABRD | |
| SCHEMBL11500 | 0.84 | TNKS (0.50) | TNKSCA1CA2GABRPGABRD | |
| SCHEMBL9363 | 0.84 | GABRP (0.52) | TNKSCA1CA2GABRPGABRD | |
| SCHEMBL8435 | 0.83 | MAPK14 (0.56) | TNKSCA1CA2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| EP-3444242-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2019-02-20 | — | — | EP | claimed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | claimed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | claimed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | claimed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | claimed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3444242-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2019-02-20 | — | — | EP | disclosed |
| EP-2496567-B1 | NOVEL BENZOPYRAN KINASE MODULATORS | RHIZEN PHARMACEUTICALS S A (CH) | 2017-07-12 | — | — | EP | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | TNKS 487/4885CA1 4598/4885CA2 3153/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | TNKS 362/4885CA1 4615/4885CA2 3756/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | TNKS 362/4885CA1 4615/4885CA2 3756/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | TNKS 362/4885CA1 4615/4885CA2 3756/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | TNKS 362/4885CA1 4615/4885CA2 3756/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | TNKS 662/4885CA1 4543/4885CA2 3288/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | TNKS 362/4885CA1 4615/4885CA2 3756/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | TNKS 362/4885CA1 4615/4885CA2 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.